Daniel F Alonso Selected Research

beta-chimaerin

1/2005	Role of beta2-chimaerin in the behaviour of murine mammary carcinoma cells in response to extracellular matrix components.
5/2003	Inhibition of aggressiveness of metastatic mouse mammary carcinoma cells by the beta2-chimaerin GAP domain.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel F Alonso Research Topics

Disease

68	Neoplasms (Cancer) 10/2020 - 01/2002
24	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2002
23	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2002
16	Carcinoma (Carcinomatosis) 01/2021 - 01/2002
15	Melanoma (Melanoma, Malignant) 07/2012 - 03/2002
9	Lung Neoplasms (Lung Cancer) 01/2018 - 12/2003
7	Hemorrhage 10/2020 - 09/2002
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2018 - 12/2007
6	Experimental Melanoma 07/2012 - 12/2002
4	Colorectal Neoplasms (Colorectal Cancer) 10/2020 - 01/2017
4	Retinoblastoma (Glioblastoma, Retinal) 12/2016 - 03/2010
4	Neuroblastoma 01/2016 - 03/2010
3	COVID-19 09/2021 - 09/2020
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2018 - 02/2007
2	Colonic Neoplasms (Colon Cancer) 07/2020 - 12/2010
2	Disease Progression 01/2020 - 05/2008
2	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 01/2017
2	Lewis Lung Carcinoma 01/2017 - 01/2012
2	Circulating Neoplastic Cells 01/2016 - 01/2015
2	Carcinogenesis 01/2014 - 01/2012
2	Residual Neoplasm 09/2008 - 12/2006
2	Lymphatic Metastasis 11/2006 - 09/2002
1	Rectal Neoplasms (Rectal Cancer) 10/2020
1	Body Weight (Weight, Body) 07/2020
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2017

Drug/Important Bio-Agent (IBA)

25	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 01/2021 - 09/2002
20	Peptides (Polypeptides)IBA 01/2020 - 01/2008
17	GangliosidesIBA 08/2018 - 03/2002
16	Vasopressins (Vasopressin)IBA 10/2020 - 09/2002
15	VaccinesIBA 12/2015 - 03/2002
12	CIGB-300IBA 01/2020 - 10/2004
8	EnzymesIBA 09/2018 - 01/2002
7	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2019 - 11/2006
7	Monoclonal AntibodiesIBA 08/2018 - 03/2002
7	racotumomabIBA 08/2018 - 01/2010
7	AntigensIBA 08/2018 - 03/2002
7	Messenger RNA (mRNA)IBA 12/2016 - 05/2008
5	Hemostatics (Antihemorrhagics)IBA 10/2020 - 09/2002
5	Cytostatic AgentsIBA 01/2020 - 01/2009
5	Casein Kinase II (Casein Kinase 2)IBA 01/2017 - 10/2004
5	von Willebrand FactorIBA 10/2015 - 11/2006
4	Arginine Vasopressin (Argipressin)IBA 01/2020 - 10/2008
4	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2016 - 01/2002
4	Proteins (Proteins, Gene)FDA Link 10/2011 - 01/2003
4	G(M3) GangliosideIBA 01/2011 - 12/2002
3	Antiviral Agents (Antivirals)IBA 09/2021 - 09/2020
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2020 - 10/2004
3	AntibodiesIBA 08/2018 - 02/2007
3	Matrix Metalloproteinases (MMPs)IBA 01/2017 - 01/2005
3	Cancer VaccinesIBA 07/2012 - 03/2002
3	Sulfoglycosphingolipids (Sulfatides)IBA 01/2012 - 02/2007
3	Cyclic PeptidesIBA 07/2011 - 10/2004
2	Ivermectin (Mectizan)FDA Link 09/2021 - 07/2021
2	Biological ProductsIBA 07/2020 - 01/2012
2	Antineoplastic Agents (Antineoplastics)IBA 07/2020 - 10/2010
2	Complement System Proteins (Complement)IBA 04/2019 - 01/2016
2	Pharmaceutical PreparationsIBA 01/2018 - 10/2011
2	Transcription Factors (Transcription Factor)IBA 12/2016 - 07/2015
2	aluminum sulfate (alum)IBA 01/2016 - 01/2012
2	Carmustine (FIVB)FDA Link 01/2016 - 09/2008
2	valyl(4)-glutaminyl(5)- desmopressinIBA 01/2016 - 12/2011
2	Monomeric GTP-Binding ProteinsIBA 01/2014 - 01/2014
2	GD2 gangliosideIBA 09/2013 - 03/2010
2	(N- acetylneuraminyl)- galactosylglucosylceramide N-acetylgalactosaminyltransferaseIBA 09/2013 - 03/2010
2	Anti-Idiotypic AntibodiesIBA 01/2013 - 12/2003
2	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2012 - 01/2012
2	CMPacetylneuraminate monooxygenase (CMP-N-acetylneuraminate monooxygenase)IBA 07/2012 - 12/2009
2	Neoplasm Antigens (Tumor Antigens)IBA 07/2012 - 01/2012
2	NucleophosminIBA 04/2012 - 10/2011
2	GlycolipidsIBA 01/2012 - 03/2002
2	Aluminum Hydroxide (Algeldrate)FDA Link 01/2012 - 01/2012
2	Cell-Penetrating PeptidesIBA 07/2011 - 01/2008
2	Formaldehyde (Formol)FDA Link 01/2011 - 01/2010
2	ParaffinIBA 01/2011 - 01/2010
2	N-glycolylneuraminyllactosylceramide (HD3)IBA 01/2011 - 01/2010
2	Tissue Inhibitor of Metalloproteinase-1IBA 11/2006 - 01/2003
2	Metalloproteases (Metalloproteinases)IBA 10/2006 - 01/2005
2	Peptide Hydrolases (Proteases)FDA Link 10/2006 - 01/2002
2	beta-chimaerinIBA 01/2005 - 05/2003
1	Free RadicalsIBA 07/2020
1	Polylactic Acid-Polyglycolic Acid CopolymerIBA 11/2018
1	Polysaccharides (Glycans)IBA 09/2018
1	Conditioned Culture MediaIBA 01/2017
1	matrigelIBA 01/2017
1	SynaptophysinIBA 01/2017
1	Chromogranin AIBA 01/2017
1	NeuropeptidesIBA 01/2017
1	Phosphopyruvate Hydratase (Enolase)IBA 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2016

Therapy/Procedure

14	Therapeutics 01/2020 - 03/2002
8	Drug Therapy (Chemotherapy) 10/2020 - 09/2008
8	Immunotherapy 01/2016 - 11/2004
3	Intravenous Administration 01/2017 - 09/2008
2	Radiotherapy 10/2020 - 01/2016
2	Blood Transfusion (Blood Transfusions) 09/2018 - 11/2017
2	Operative Surgical Procedures 01/2015 - 12/2010
1	Oral Administration 07/2020
1	Castration 01/2019
1	Cytoreduction Surgical Procedures 11/2017
1	Hyperthermic Intraperitoneal Chemotherapy 11/2017